More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/6-ECDCA [459789-99-2]
Chemical Structure
Chemical Structure
Chemical Structure

6-ECDCA [459789-99-2]

Research Use Only
AG-CR1-3560
AdipoGen Life Sciences
CAS Number459789-99-2
DownloadDatasheet
DownloadMSDS
Product group Chemicals
Estimated Purity>95% (NMR)
Molecular Weight420.6
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    6-ECDCA [459789-99-2]
  • Delivery Days Customer
    10
  • CAS Number
    459789-99-2
  • Certification
    Research Use Only
  • Estimated Purity
    >95% (NMR)
  • Hazard Information
    Non-hazardous
  • Molecular Formula
    C26H44O4
  • Molecular Weight
    420.6
  • Scientific Description
    Chemical. CAS: 459789-99-2. Formula: C26H44O4. MW: 420.6. Potent and selective FXR agonist (EC50= 99nM). Induces SHP in HSCs to suppress TIMP-1 expression. Apoptosis inducer. Protects against liver fibrosis development in rat in vivo. Displays anticholeretic activity in rat in vivo. Promotes preadipocyte differentiation. Regulates adipogenesis and insulin signaling in vivo. Inhibits vascular smooth muscle cell inflammation and migration. - Potent and selective farnesoid X receptor FXR agonist (EC50= 99nM) [1]. Induces SHP in HSCs to suppress TIMP-1 expression [2]. Apoptosis inducer [2]. Protects against liver fibrosis development in rat in vivo [2]. Displays anticholeretic activity in rat in vivo [3]. Promotes preadipocyte differentiation [4]. Regulates adipogenesis and insulin signaling in vivo [4]. Inhibits vascular smooth muscle cell inflammation and migration [5].
  • SMILES
    [H][C@@]12C[C@H](O)CC[C@]1(C)C1CC[C@]3(C)[C@H](CCC3C1[C@H](O)[C@@H]2CC)[C@H](C)CCC(O)=O
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352200

References

  • 6r-Ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity: R. Pellicciari, et al.; J. Med. Chem. 45, 3569 (2002)
  • A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis: S. Fiorucci, et al.; J. Pharmacol. Exp. Ther. 314, 584 (2005)
  • Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis: S. Fiorucci, et al.; J. Pharmacol. Exp. Ther. 313, 604 (2005)
  • The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo: G. Rizzo, et al.; Mol. Pharmacol. 70, 1164 (2006)
  • Farnesoid X receptor ligands inhibit vascular smooth muscle cell inflammation and migration: Y.T. Li, et al.; Arterioscler. Thromb. Vasc. Biol. 27, 2606 (2007)